TARGET BP I Clinical Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 300 participants.

Also called NCT02910414

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02910414
Other papers using this trial's data
  • Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial Circulation, 2024-06-11 DOI, PubMed 38587557

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT02910414. Randomized; triple masking; primary purpose treatment. Start 2019-07-22 (actual); primary completion 2023-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TARGET BP I Clinical Trial
Acronym
TARGET BP I
Condition
Hypertension
Intervention (Drug)
Dehydrated alcohol
Intervention (Device)
Peregrine System Kit (Sham Procedure)
Lead sponsor
Ablative Solutions, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02910414
Content hash
0f0a40a0306aed537a42e9ef8d3b7cac687debe98981bdb822289180a8f937f7